Related Experiment Video
Updated: Jan 20, 2026
Patient-derived Tumor Xenografting: A Technique to Generate Experimental Mouse Model for Evaluating Urothelial Cell Carcinoma
Published on: April 30, 2023
Erdafitinib to treat urothelial carcinoma
1Mayo Clinic College of Medicine, Hematology/Oncology Clinical Pharmacist, University of Minnesota Medical Center, Minneapolis, Minnesota, USA. Kirollos11@gmail.com.
Abstract:
Erdafitinib is the first Food and Drug Administration (FDA)-approved oral pan-fibroblast growth factor receptor (FGFR) kinase inhibitor that binds to four FGFRs (FGFR-1 to -4), leading to decreased cell signaling and cellular apoptosis. Erdafitinib also binds to RET, colony-stimulating factor 1 receptor (CSF-1R), platelet-derived growth factor receptor α and β (PDGFR-α and PDGFR-β), Fms-related tyrosine kinase 4 (FLT4), KIT and vascular endothelial growth factor receptor 2 (VEGFR-2), exhibiting additional antitumor mechanisms resulting in cell kill. In this article, we provide a comprehensive review of the preclinical and clinical activity of erdafitinib, which has been recently approved in the U.S. for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3/FGFR2 genetic alterations following progression during or after at least one line of platinum-containing chemotherapy and within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Erdafitinib is the first oral treatment option for patients with urothelial carcinoma.
Insights
Erdafitinib is a new oral medication approved for advanced urothelial carcinoma. It targets fibroblast growth factor receptors (FGFRs), offering a novel treatment for patients with specific genetic alterations.
Area of Science:
- Oncology
- Pharmacology
Background:
- Erdafitinib is the first FDA-approved oral pan-fibroblast growth factor receptor (FGFR) kinase inhibitor.
- It targets FGFR-1 to -4 and other kinases like RET and VEGFR-2, mediating antitumor effects.
Purpose of the Study:
- To provide a comprehensive review of the preclinical and clinical activity of erdafitinib.
- To highlight its recent FDA approval for urothelial carcinoma treatment.
Main Methods:
- Review of preclinical data on erdafitinib's mechanism of action.
- Analysis of clinical trial data evaluating erdafitinib's efficacy and safety.
Main Results:
- Erdafitinib demonstrates activity against multiple FGFRs and other tyrosine kinases.
- It has been approved for adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3/FGFR2 alterations.
Conclusions:
- Erdafitinib represents a significant advancement, being the first oral treatment option for this patient population.
- Its targeted inhibition of FGFR pathways offers a new therapeutic strategy in urothelial carcinoma.
More Related Videos
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
09:16Ex Vivo Organoid Model of Adenovirus-Cre Mediated Gene Deletions in Mouse Urothelial Cells
Published on: May 5, 2022
Related Concept Videos
03:32Patient-derived Tumor Xenografting: A Technique to Generate Experimental Mouse Model for Evaluating Urothelial Cell Carcinoma
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
09:16Ex Vivo Organoid Model of Adenovirus-Cre Mediated Gene Deletions in Mouse Urothelial Cells
06:39Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
05:35Ex Vivo Analysis of Mechanically Activated Ca2+ Transients in Urothelial Cells